KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Accumulated Expenses: 2010-2024

Historic Other Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $14.5 million.

  • Nektar Therapeutics' Other Accumulated Expenses fell 32.55% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 32.55%. This contributed to the annual value of $14.5 million for FY2024, which is 42.84% up from last year.
  • Nektar Therapeutics' Other Accumulated Expenses amounted to $14.5 million in FY2024, which was up 42.84% from $10.1 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Other Accumulated Expenses ranged from a high of $21.0 million in FY2020 and a low of $7.0 million during FY2022.
  • For the 3-year period, Nektar Therapeutics' Other Accumulated Expenses averaged around $10.5 million, with its median value being $10.1 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 70.09% in 2020, then slumped by 54.73% in 2022.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Other Accumulated Expenses stood at $21.0 million in 2020, then decreased by 26.29% to $15.5 million in 2021, then plummeted by 54.73% to $7.0 million in 2022, then spiked by 44.48% to $10.1 million in 2023, then skyrocketed by 42.84% to $14.5 million in 2024.